NCT07635563Phase 2Recruiting

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-04Estimated

Enrollment · participants120Estimated

Source updated2026-09-22Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-27 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Obstructive Sleep Apnea (OSA)

Treatments or interventions studied

IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamideDrug
IHL-42X: 5 mg dronabinol + 125 mg acetazolamideDrug
IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamideDrug
IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamideDrug
IHL-42X: 5 mg dronabinol + 250 mg acetazolamideDrug
IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamideDrug
IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamideDrug
IHL-42X: 5 mg dronabinol + 375 mg acetazolamideDrug
IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamideDrug
Placebo: Negative controlDrug

Primary outcomes · main study measures

measure: Change in AHI4 at the end of each treatment period compared to baseline; description: To assess the change in efficacy at the end of each dosing period compared with baseline.; timeFrame: Each treatment period (28 days)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history